Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Net Margin (2021 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Net Margin data on record, last reported at 4.11% in Q4 2025.

  • For Q4 2025, Net Margin rose 3065.0% year-over-year to 4.11%; the TTM value through Dec 2025 reached 14.21%, up 4777.0%, while the annual FY2025 figure was 14.72%, 4845.0% up from the prior year.
  • Net Margin reached 4.11% in Q4 2025 per TARS's latest filing, up from 10.69% in the prior quarter.
  • Across five years, Net Margin topped out at 32.97% in Q2 2021 and bottomed at 4286.98% in Q4 2021.
  • Average Net Margin over 5 years is 722.96%, with a median of 62.73% recorded in 2024.
  • The widest YoY moves for Net Margin: up 415072bps in 2022, down -371166bps in 2022.
  • A 5-year view of Net Margin shows it stood at 4286.98% in 2021, then skyrocketed by 97bps to 136.26% in 2022, then tumbled by -138bps to 324.72% in 2023, then skyrocketed by 89bps to 34.76% in 2024, then soared by 88bps to 4.11% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 4.11% in Q4 2025, 10.69% in Q3 2025, and 19.67% in Q2 2025.